Comparative Pharmacology
Head-to-head clinical analysis: CIPROFLOXACIN HYDROCHLORIDE versus MOXAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPROFLOXACIN HYDROCHLORIDE versus MOXAM.
CIPROFLOXACIN HYDROCHLORIDE vs MOXAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial DNA gyrase and topoisomerase IV, thereby inhibiting DNA replication and transcription.
Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with DNA replication, transcription, repair, and recombination.
500-750 mg orally every 12 hours; 400 mg intravenously every 8-12 hours.
400 mg orally every 24 hours for 7-14 days.
None Documented
None Documented
Terminal half-life 4 hours (3-5 h) in normal renal function; prolonged to 5-10 h in mild-to-moderate renal impairment and >10 h in severe impairment (CrCl <30 mL/min).
Terminal elimination half-life: 6-8 hours; prolonged in renal impairment (up to 20 hours with CrCl <30 mL/min).
Renal: 50-70% unchanged drug; biliary/fecal: 15-25% (partly as metabolites).
Renal: ~70% unchanged; biliary/fecal: ~20% as unchanged drug and metabolites; minor metabolism via glucuronidation.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic